Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study.
Stein A, Arnold D, Thuss-Patience PC, Moehler M, Grothe W, Seufferlein T, Reinacher-Schick A, Geissler M, Hofheinz RD, Schmoll HJ. Stein A, et al. Among authors: geissler m. Acta Oncol. 2014 Mar;53(3):392-8. doi: 10.3109/0284186X.2013.833346. Epub 2013 Sep 12. Acta Oncol. 2014. PMID: 24024696 Clinical Trial.
Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer.
Harder J, Ihorst G, Heinemann V, Hofheinz R, Moehler M, Buechler P, Kloeppel G, Röcken C, Bitzer M, Boeck S, Endlicher E, Reinacher-Schick A, Schmoor C, Geissler M. Harder J, et al. Among authors: geissler m. Br J Cancer. 2012 Mar 13;106(6):1033-8. doi: 10.1038/bjc.2012.18. Epub 2012 Feb 28. Br J Cancer. 2012. PMID: 22374460 Free PMC article. Clinical Trial.
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.
Schmiegel W, Reinacher-Schick A, Arnold D, Kubicka S, Freier W, Dietrich G, Geißler M, Hegewisch-Becker S, Tannapfel A, Pohl M, Hinke A, Schmoll HJ, Graeven U. Schmiegel W, et al. Among authors: geissler m. Ann Oncol. 2013 Jun;24(6):1580-7. doi: 10.1093/annonc/mdt028. Epub 2013 Mar 4. Ann Oncol. 2013. PMID: 23463625 Free article. Clinical Trial.
A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.
Moehler M, Kanzler S, Geissler M, Raedle J, Ebert MP, Daum S, Flieger D, Seufferlein T, Galle PR, Hoehler T; Arbeitsgemeinschaft Internistische Onkologie, Germany. Moehler M, et al. Among authors: geissler m. Ann Oncol. 2010 Jan;21(1):71-7. doi: 10.1093/annonc/mdp269. Epub 2009 Jul 15. Ann Oncol. 2010. PMID: 19605504 Free article. Clinical Trial.
DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma.
Ettrich TJ, Perkhofer L, von Wichert G, Gress TM, Michl P, Hebart HF, Büchner-Steudel P, Geissler M, Muche R, Danner B, Kächele V, Berger AW, Güthle M, Seufferlein T. Ettrich TJ, et al. Among authors: geissler m. BMC Cancer. 2016 Jan 15;16:21. doi: 10.1186/s12885-016-2052-4. BMC Cancer. 2016. PMID: 26772812 Free PMC article. Clinical Trial.
PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.
Vogel A, Kasper S, Bitzer M, Block A, Sinn M, Schulze-Bergkamen H, Moehler M, Pfarr N, Endris V, Goeppert B, Merx K, Schnoy E, Siveke JT, Michl P, Waldschmidt D, Kuhlmann J, Geissler M, Kahl C, Evenkamp R, Schmidt T, Kuhlmann A, Weichert W, Kubicka S. Vogel A, et al. Among authors: geissler m. Eur J Cancer. 2018 Mar;92:11-19. doi: 10.1016/j.ejca.2017.12.028. Epub 2018 Feb 3. Eur J Cancer. 2018. PMID: 29413685 Clinical Trial.
[Specific treatment situations in metastatic colorectal cancer].
Arnold D, Schmoll HJ, Lang H, Knoefel WT, Ridwelski K, Trarbach T, Staib L, Kirchner T, Geissler M, Seufferlein T, Amthauer H, Riess H, Schlitt HJ, Piso P. Arnold D, et al. Among authors: geissler m. Onkologie. 2010;33 Suppl 4:8-18. doi: 10.1159/000308447. Epub 2010 Apr 23. Onkologie. 2010. PMID: 20431307 Review. German.
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ, Berger AW, Perkhofer L, Daum S, König A, Dickhut A, Wittel U, Wille K, Geissler M, Algül H, Gallmeier E, Atzpodien J, Kornmann M, Muche R, Prasnikar N, Tannapfel A, Reinacher-Schick A, Uhl W, Seufferlein T. Ettrich TJ, et al. Among authors: geissler m. BMC Cancer. 2018 Dec 29;18(1):1298. doi: 10.1186/s12885-018-5183-y. BMC Cancer. 2018. PMID: 30594153 Free PMC article.
FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109).
Modest DP, Martens UM, Riera-Knorrenschild J, Greeve J, Florschütz A, Wessendorf S, Ettrich T, Kanzler S, Nörenberg D, Ricke J, Seidensticker M, Held S, Buechner-Steudel P, Atzpodien J, Heinemann V, Seufferlein T, Tannapfel A, Reinacher-Schick AC, Geissler M. Modest DP, et al. Among authors: geissler m. J Clin Oncol. 2019 Dec 10;37(35):3401-3411. doi: 10.1200/JCO.19.01340. Epub 2019 Oct 14. J Clin Oncol. 2019. PMID: 31609637 Clinical Trial.
240 results